Related Experiment Video
Updated: Apr 7, 2026

Experimental Human Pneumococcal Carriage
Published on: February 15, 2013
U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination
Marie R Griffin1, Yuwei Zhu, Matthew R Moore
1Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville, TN 37212, USA. marie.griffin@vanderbilt.edu
Insights
The 7-valent pneumococcal conjugate vaccine (PCV7) sustained reductions in childhood pneumonia hospitalizations. Significant declines in adult pneumonia hospitalizations were also observed following PCV7 introduction.
Area of Science:
- Epidemiology
- Immunization
- Public Health
Background:
- The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced to the U.S. childhood immunization schedule in 2000.
- PCV7 significantly decreased invasive pneumococcal disease and pneumonia hospitalizations in young children.
- Concerns existed regarding potential increases in non-vaccine serotype diseases.
Purpose of the Study:
- To assess if the reduction in pneumonia hospitalizations among young children was sustained through 2009.
- To determine if pneumonia hospitalizations declined in older age groups after PCV7 introduction.
Main Methods:
- Utilized the Nationwide Inpatient Sample database to estimate annual pneumonia hospitalization rates.
- Classified hospitalizations as pneumonia if it was the primary diagnosis or followed sepsis, meningitis, or empyema.
- Compared pre-PCV7 rates (1997-1999) with post-PCV7 rates (2007-2009) to calculate annual declines.
Main Results:
- Pneumonia hospitalizations declined by 551.1 per 100,000 children under 2 years, totaling 47,000 fewer annual hospitalizations.
- Adults aged 85+ experienced a decline of 1300.8 per 100,000, equating to 73,000 fewer annual hospitalizations.
- Overall age-adjusted annual reduction was 54.8 per 100,000, resulting in approximately 168,000 fewer pneumonia hospitalizations annually.
Conclusions:
- The observed declines in childhood pneumonia hospitalizations were sustained a decade after PCV7 introduction.
- Substantial reductions in pneumonia hospitalizations were also evident across various adult age groups.
- These findings underscore the sustained public health impact of PCV7 on pneumonia burden.
Background:
The introduction of 7-valent pneumococcal conjugate vaccine (PCV7) into the U.S. childhood immunization schedule in 2000 has substantially reduced the incidence of vaccine-serotype invasive pneumococcal disease in young children and in unvaccinated older children and adults. By 2004, hospitalizations associated with pneumonia from any cause had also declined markedly among young children. Because of concerns about increases in disease caused by nonvaccine serotypes, we wanted to determine whether the reduction in pneumonia-related hospitalizations among young children had been sustained through 2009 and whether such hospitalizations in older age groups had also declined.
Methods:
We estimated annual rates of hospitalization for pneumonia from any cause using the Nationwide Inpatient Sample database. The reason for hospitalization was classified as pneumonia if pneumonia was the first listed diagnosis or if it was listed after a first diagnosis of sepsis, meningitis, or empyema. Average annual rates of pneumonia-related hospitalizations from 1997 through 1999 (before the introduction of PCV7) and from 2007 through 2009 (well after its introduction) were used to estimate annual declines in hospitalizations due to pneumonia.
Results:
The annual rate of hospitalization for pneumonia among children younger than 2 years of age declined by 551.1 per 100,000 children (95% confidence interval [CI], 445.1 to 657.1), which translates to 47,000 fewer hospitalizations annually than expected on the basis of the rates before PCV7 was introduced. The rate for adults 85 years of age or older declined by 1300.8 per 100,000 (95% CI, 984.0 to 1617.6), which translates to 73,000 fewer hospitalizations annually. For the three age groups of 18 to 39 years, 65 to 74 years, and 75 to 84 years, the annual rate of hospitalization for pneumonia declined by 8.4 per 100,000 (95% CI, 0.6 to 16.2), 85.3 per 100,000 (95% CI, 7.0 to 163.6), and 359.8 per 100,000 (95% CI, 199.6 to 520.0), respectively. Overall, we estimated an age-adjusted annual reduction of 54.8 per 100,000 (95% CI, 41.0 to 68.5), or 168,000 fewer hospitalizations for pneumonia annually.
Conclusions:
Declines in hospitalizations for childhood pneumonia were sustained during the decade after the introduction of PCV7. Substantial reductions in hospitalizations for pneumonia among adults were also observed. (Funded by the Centers for Disease Control and Prevention.).
More Related Videos
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
12:21A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
Published on: September 28, 2022
Related Concept Videos
Vaccinations
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....